Nirogacestat dihydrobromide: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Nirogacestat dihydrobromide: clinical details
Prescribing considerations
- Initiation and monitoring should be undertaken by a physician experienced in anticancer therapy.
- Assess pregnancy status and contraception before treatment; discuss potential ovarian toxicity and possible effects on fertility.
- Review CYP3A4 interactions, acid-reducing therapy and all herbal or non-prescription products.
- Use is not recommended in severe renal or severe hepatic impairment because relevant data are limited.
- Safety and efficacy have not been established in children and adolescents.
Contraindications and cautions
- Hypersensitivity to nirogacestat or an excipient
- Pregnancy
- Women of childbearing potential not using highly effective contraception
- Breastfeeding
- Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption because the tablets contain lactose
Monitoring
- Diarrhoea and dermatological reactions
- Serum phosphate and potassium
- Liver function tests
- Menstrual changes and symptoms of oestrogen deficiency
- Skin examination before treatment and routinely thereafter
- Pregnancy testing where indicated
Clinical pharmacology
Nirogacestat is a reversible, non-competitive gamma-secretase inhibitor that blocks proteolytic Notch-receptor activation. It is extensively metabolised mainly by CYP3A4, is highly protein bound and has pH-dependent solubility.
Formulation and product differences
- The film-coated tablet contains lactose monohydrate and sunset yellow FCF (E110), which may cause allergic reactions.
- Tablets must be swallowed whole; breaking, chewing or crushing is unsupported.
Nirogacestat dihydrobromide preparations and strengths
Tablet
Route: Oral
Strengths: 150 mg
Nirogacestat dihydrobromide interactions
The specialist team should review all medicines and herbal products. Important interactions include:
Strong or moderate CYP3A4 inhibitors, including clarithromycin, itraconazole, erythromycin and fluconazole
These can substantially increase nirogacestat exposure and should generally be avoided.
CYP3A4 inducers, including rifampicin, carbamazepine, phenytoin, phenobarbital and St John’s wort
These may lower exposure and reduce effectiveness, so concurrent use should be avoided.
Proton-pump inhibitors and H2-receptor antagonists
Reduced stomach acidity may impair absorption; concurrent use is not recommended.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.